Effect of bulevirtide (BLV) monotherapy 2 mg/day for 48 weeks on HDV RNA levels and ALT levels in 18 patients with HDV-related cirrhosis and clinically significant portal hypertension. Credit: Journal of Hepatology In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus...
